Ondine Biomedical Named Finalist for Best Communications Award at the 2025 European Mediscience Awards Ondine Biomedical Inc. has been named a finalist for the Best Communications Award at the 2025 European Mediscience Awards, the premier annual event celebrating excellence in the life sciences sector across Europe. Ondine  is a [...]

First UK Deployment at Mid Yorkshire Teaching NHS Trust reduces SSI rates by 71% with Steriwave Nasal Photodisinfection Ondine Biomedical Inc. (LON: OBI) reports that results from the first NHS deployment of Steriwave® nasal decolonization technology at Mid Yorkshire Teaching NHS Trust (Mid Yorks) have demonstrated a substantial reduction [...]

First patients recruited into Steriwave ICU pilot study and related Issue of Shares Ondine Biomedical Inc. (LON: OBI), a global leader in light-activated antimicrobial technologies, is pleased to announce that patient recruitment has commenced in an intensive care unit (ICU) pilot study at Royal Columbian Hospital (RCH) in New [...]

Quebec’s Sherbrooke University Hospital Cuts surgical site infections in patients undergoing spine surgery by 78% Results demonstrated that patients treated with Steriwave nasal photodisinfection (aPDT) experienced >78% fewer SSIs than untreated patients. Hospital length of stay also decreased by 30% in the Steriwave treated patients. La Malbaie, Quebec – [...]

Innovative light-activated antimicrobial treatment has potential to become first FDA-approved nasal decolonization treatment for prevention of surgical site infections Ondine’s light-activated antimicrobial therapy for nasal decolonization would apply to more than 35 million major surgical procedures in the USA annually. Surgical site infections (“SSIs”) account for 20% of all [...]

This Announcement uses a US$:£ exchange rate of 1 : 0.808210 as at 16:30 (GMT) on 2 January 2025. Ondine Biomedical Inc. (LON: OBI), a Canadian life sciences company developing light-activated antimicrobial treatments, is pleased to announce that hInsight-NX, LLC, a subsidiary of HCA Healthcare, Inc., a leading healthcare [...]

Ondine Biomedical Inc. (LON: OBI), a Canadian life sciences company, has enrolled and treated the first patient in the Light-Activated Antimicrobial Therapy to Prevent Surgical Site Infections (‘LANTERN’) Phase 3 clinical trial. The trial, involving approximately 5,000 patients in 14 hospitals, is evaluating Ondine’s non-antibiotic nasal photodisinfection technology, branded [...]

Updated November 15, 2025 to reflect further funds raised. Canadian life sciences company Ondine Biomedical announces that it is accelerating its final preparations for a Q4 2024 start to its key pivotal US Phase 3 trial following its recent successful raise of Cdn $19.2 million (c. £10.8 million). Alongside [...]